Sibylle Loibl
Papers
1
Total Citations
2
H-Index
1
About
Sibylle Loibl is a leading figure in breast cancer research, with a focus on neoadjuvant therapy, molecular tumor subtyping, and the tumor microenvironment. Her major contributions include pioneering the use of RNA-based molecular profiling to predict responses to chemotherapy, as demonstrated in the GeparQuinto-PREDICT substudy. This work established standardized cutoffs for assessing ESR1 and HER2 expression in FFPE tissue, enabling more precise tumor classification. Loibl also advanced understanding of the immunological infiltrate—particularly intratumoral and stromal lymphocytes—as a key predictor of treatment outcomes. Her research has garnered over 10,000 citations, reflecting its profound impact on clinical practice and personalized oncology. Notably, she has led numerous landmark clinical trials and serves as a professor at Goethe University Frankfurt, where she continues to shape the field. Her work bridges molecular biology and patient care, offering critical insights for students and researchers aiming to improve breast cancer prognosis and therapy.
Research Focus
Key Achievements
Top Papers
- 1